ETC
-
Aggrastat Inj.
- Ingredient
Tirofiban Hydrochloride Hydrate
- Content
14.05mg/50ml (12.5mg/50ml as tirofiban)
- Indication
Co-administration with heparin in the patients who are:
– target patients in the treatment of acute coronary syndrome (ACS)
– patients with percutaneous transluminal coronary angioplasty (PTCA) or atherectomyIt has been shown to reduce the incidence of death, myocardial infarction, or combined endpoints of refractory ischemia/recardiac procedures.
-
Allegra Tab. 180mg
- Ingredient
Fexofenadine Hydrochloride
- Content
180mg
- Indication
Relief of symptoms associated with allergic skin disease (chronic idiopathic urticaria).
-
Allegra Tab. 30mg
- Ingredient
Fexofenadine Hydrochloride
- Content
30mg
- Indication
Relief of symptoms associated with seasonal allergic rhinitis and allergic skin diseases (chronic idiopathic urticaria)
-
Amaryl M Tab.
- Ingredient
Glimepiride/Metformin Hydrochloride
- Content
1/250mg, 1/500mg, 2/500mg
- Indication
Management of type 2 diabetes mellitus as an adjunct to diet and exercise in following cases:
-When glimepiride or metformin monotherapy is insufficient to control blood glucose level
-As an alternative to combination therapy of glimepiride and metformin
-
Amaryl Mex SR Tab.
- Ingredient
Glimepiride/Metformin Hydrochloride
- Content
2mg/500mg
- Indication
Management of type 2 diabetes mellitus as an adjunct to diet and exercise in following cases:
-When sulfonylurea or metformin monotherapy is insufficient to control blood glucose level
-As an alternative to combination therapy of sulfonylurea and metformin
-
Amaryl Tab.
- Ingredient
Glimepiride
- Content
1mg, 2mg, 4mg
- Indication
Management of type 2 diabetes mellitus as an adjunct to diet and exercise
1) It is administered as monotherapy
2) It is administered in combination therapy
-When oral hypoglycemic agent is insufficient to control blood glucose level, this drug can be co-administered with insulin
-When sulfonylurea or metformin monotherapy is insufficient to control blood glucose level, this drug can be co-administered with metformin
-
Arixtra Inj.
- Ingredient
Fondaparinux Sodium
- Content
2.5mg/0.5ml (pre-filled syringe)
- Indication
1) Prophylaxis of venous thromboembolism in patients undergoing major orthopedic surgery of the lower limb, such as hip fracture surgery, knee surgery, or hip replacement surgery
2) Prophylaxis of venous thromboembolism in patients underwent abdominal surgery, such as abdominal cancer surgery who are deemed to have a high risk of thromboembolic complications
3) Prophylaxis of venous thromboembolism in patients with limited mobility due to acute diseases such as heart failure (NYHA class Ⅲ or Ⅳ), acute respiratory disease, acute infection or inflammatory disease and medical patients who are deemed to have a high risk of venous thromboembolism
4) Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in patients who are not covered by emergency invasive management (Percutaneous Coronary Intervention(PCI) within 120 minutes)
5) Treatment of ST segment elevation myocardial infarction (STEMI) in patients who are being treated with thrombolytic agents or initially not receiving other forms of reperfusion therapy